Jaksa A - Search Results

1

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.

Jaksa A, Gibbs L, Kent S, Rowark S, Duffield S, Sharma M, Kincaid L, Ali AK, Patrick AR, Govil P, Jonsson P, Gatto N. Jaksa A, et al. BMJ Open. 2022 Oct 17;12(10):e064662. doi: 10.1136/bmjopen-2022-064662. BMJ Open. 2022. PMID: 36253039 Free PMC article.

2

Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.

Jaksa A, Wu J, Jónsson P, Eichler HG, Vititoe S, Gatto NM. Jaksa A, et al. J Comp Eff Res. 2021 Jun;10(9):711-731. doi: 10.2217/cer-2020-0228. Epub 2021 Apr 30. J Comp Eff Res. 2021. PMID: 33928789 Free article.

3

The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework.

Gatto NM, Campbell UB, Rubinstein E, Jaksa A, Mattox P, Mo J, Reynolds RF. Gatto NM, et al. Among authors: jaksa a. Clin Pharmacol Ther. 2022 Jan;111(1):122-134. doi: 10.1002/cpt.2466. Epub 2021 Dec 1. Clin Pharmacol Ther. 2022. PMID: 34716990 Free PMC article. Review.

4

Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot.

Jaksa A, Bloudek L, Carlson JJ, Shah K, Chen Y, Patrick AR, McKenna A, Campbell JD. Jaksa A, et al. Int J Technol Assess Health Care. 2022 Mar 14;38(1):e32. doi: 10.1017/S0266462322000162. Int J Technol Assess Health Care. 2022. PMID: 35357284

5

A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.

Jaksa A, Louder A, Maksymiuk C, Vondeling GT, Martin L, Gatto N, Richards E, Yver A, Rosenlund M. Jaksa A, et al. Value Health. 2022 Dec;25(12):1967-1976. doi: 10.1016/j.jval.2022.05.016. Epub 2022 Jun 25. Value Health. 2022. PMID: 35760714 Free article. Review.

6

Transferability of real-world data across borders for regulatory and health technology assessment decision-making.

Jaksa A, Arena PJ, Chan KKW, Ben-Joseph RH, Jónsson P, Campbell UB. Jaksa A, et al. Front Med (Lausanne). 2022 Nov 16;9:1073678. doi: 10.3389/fmed.2022.1073678. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36465931 Free PMC article.

7

Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.

Jaksa A, Arena PJ, Gatto N. Jaksa A, et al. J Comp Eff Res. 2023 Nov;12(11):e230125. doi: 10.57264/cer-2023-0125. Epub 2023 Oct 10. J Comp Eff Res. 2023. PMID: 37815792 Free PMC article. Review.

8

Nice Restrictiveness Compared To the Market Authorization.

Jaksa A, Westbrook L, Rubinstein E, Daniel K, Ho YS. Jaksa A, et al. Value Health. 2014 Nov;17(7):A438-9. doi: 10.1016/j.jval.2014.08.1142. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201164 Free article. No abstract available.

9

Nice Restrictiveness Compared to the Market Authorization In Oncology And Non-Oncology Reviews.

Jaksa A, Westbrook L, Rubinstein E, Daniel K, Ho YS. Jaksa A, et al. Value Health. 2014 Nov;17(7):A660-1. doi: 10.1016/j.jval.2014.08.2422. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202403 Free article. No abstract available.

10

Learning from the past to advance tomorrow's real-world evidence: what demonstration projects have to teach us.

Jaksa A, Mahendraratnam N. Jaksa A, et al. J Comp Eff Res. 2021 Nov;10(16):1169-1173. doi: 10.2217/cer-2021-0166. Epub 2021 Sep 14. J Comp Eff Res. 2021. PMID: 34519543 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters